Core Insights - X4 Pharmaceuticals is progressing with its pivotal 4WARD Phase 3 trial for chronic neutropenia, aiming for enrollment completion by Q3 2026 [1][2] - The European Medicines Agency has issued a positive opinion recommending marketing authorization for mavorixafor to treat WHIM syndrome in the EU [1][2] - The company has sufficient cash runway through 2028, supported by recent equity financings and operational cost reductions [1][4] Recent Accomplishments and Updates - The 4WARD trial is focused on evaluating mavorixafor's efficacy, safety, and tolerability in patients with chronic neutropenia, with over 100 active clinical trial sites established [6][8] - The positive opinion from the EMA will be reviewed by the European Commission, with a final decision expected in Q2 2026 [6][8] - The company has implemented measures to enhance trial enrollment, including expanding clinical sites and increasing physician engagement [6] Financial Results - For Q4 2025, net product sales were $2.3 million, and for the full year, they reached $6.5 million, primarily from XOLREMDI sales in the U.S. [4][13] - Total revenue for Q4 2025 was $2.6 million, while for the full year, it was $35.1 million [4][13] - The operating loss for Q4 2025 was $23.7 million, with a net loss of $23.9 million, or $(0.22) per share [4][13] Balance Sheet Overview - As of December 31, 2025, cash and cash equivalents totaled $217.0 million, with total assets amounting to $290.5 million [4][14] - The company reported total stockholders' equity of $186.3 million, indicating a strong financial position [4][14]